Meropenem was compared with imipenem/cilastatin for the treatment of serious bacterial infections in a randomized, prospective multicentre study. Both study drugs were given intravenously 1 g every 8 h and no other antimicrobial agents were permitted concomitantly. Of the 204 patients enrolled, the treatment of 177 was evaluable for clinical efficacy and 115 for bacteriological efficacy. In the clinically evaluable treatment population, 75 (83%) of the 90 patients in the meropenem group and 78 (90%) of the 87 in the imipenem/cilastatin group had a single site of infection whereas the remainder had two or more sites of infection. Infections of the lower respiratory tract and peritoneal cavity predominated accounting for 95 and 75 cases respectively. Other infections included skin and soft tissue infections, complicated urinary tract infections, bacteraemia and a case of meningitis treated with meropenem and one of mediastinitis treated with imipenem/cilastatin. One hundred and nineteen (67%) patients were in an intensive care unit, 105 (59%) were receiving assisted ventilation and 93 (53%) of the patients had failed previous antibiotic therapy. One hundred and ten organisms were identified as pathogens in the meropenem group and 109 in the imipenem/cilastatin group. Overall, treatment with meropenem was clinically successful in 68 (76%) of 90 cases and imipenem/cilastatin in 67 (77%) of 87 cases and the corresponding eradication rates of bacteria were 85 of 110 (77%) and 90 of 109 (83%) respectively. Superinfections due to resistant bacteria occurred in two patients treated with meropenem and three cases given imipenem/cilastatin. No statistically significant differences in the clinical or bacteriological outcome were observed between the treatment groups for any of the infection sites analysed. Both drugs were well tolerated with adverse events considered to be related to therapy being recorded for 10 (9%) of 106 patients treated with meropenem and 12 (12%) of 98 of those who had been given imipenem/cilastatin. Empirical monotherapy with meropenem was therefore as effective and as well tolerated as that with imipenem/cilastatin for the treatment of serious bacterial infections.
Introduction
Nosocomial infection still remains one of the most important factors contributing to the mortality of hospitalized patients, especially among those given assisted artificial
•The Meropenem Serious Infection Study Group comprised the following: B. Byl (Brussels), J. M. Collard (Brussels), P. Damas (Liege), Belgium; C. Manni (Rome), G. Martinelli (Bologna), A. Nespoli (Milan), P. Zuccoli (Parma), Italy; S. J. Geroulanos (Zurich), Switzerland; R. G. Finch (Nottingham), UK. ventilation in intensive care units (ICU) . The rise in the number of resistant bacteria, particularly those that produce extended spectrum /J-lactamases conferring resistance to third-generation cephalosporins, is causing concern (Neu, 1993) . The need for broad-spectrum therapy with a regimen that is stable to the action of these /Mactamases has led to the increasing use of imipenem/cilastatin (Eckhauser et al., 1992; Rolston et al., 1992; Unertl et al., 1992; Miller et al., 1993; Norrby et al., 1993) . The broad antibacterial spectrum of imipenem/cilastatin renders it a good choice for treating nosocomial infections in seriously ill patients. Monotherapy with the carbapenem compares favourably with treatment using other agents either alone or in combination (Mouton et al., 1990; Norrby et al., 1993; Cometta et al., 1994; Fink et al., 1994) . However, treatment with imipenem/cilastatin is not without risk to this group of very sick patients who may experience convulsions and other side-effects (Calandra et al., 1988; Del Favero, 1994; Scheld, 1994) , whose mucosal surfaces may suffer an overgrowth of resistant organisms (Colardyn et al., 1984) and who may accumulate cilastatin as a result of renal failure (Keller et al., 1989) .
The new carbapenem, meropenem, has a similar spectrum of activity to that of imipenem (Jones, Barry & Thornsberry, 1989; Moellering, Eliopoulos & Sentochnik, 1989; Edwards, 1995) , but possesses a high degree of stability to renal dehydropeptidase-I and therefore, unlike imipenem, does not need to be coadministered with an enzyme inhibitor such as cilastatin. Meropenem possesses a lower potential for inducing seizures in laboratory animals (Patel & Giles, 1989; De Sarro et al., 1995) and the data from a large clinical trial programme, including studies for the treatment of meningitis, shows the drug to have been well tolerated by the central nervous system (Klugman & Dagan, 1995; Norrby et al., 1995) .
The aim of the present study was to compare the clinical and bacteriological efficacy and tolerability of meropenem with that of imipenem/cilastatin for the empirical treatment of serious bacterial infections caused by susceptible pathogens.
Methods

Study design
This was a multicentre, randomized, open, controlled phase III clinical study recruiting patients from ten hospitals. Each of the ethics committees had given written approval before starting the study and all patients or their next of kin gave their informed consent.
Inclusion and exclusion criteria
Hospitalized patients who were 18 years or older and who were deemed to require parenteral antibiotic therapy for a serious bacterial infection were eligible for entry to the study provided that the pathogen responsible, or at least one pathogen involved in a polymicrobial infection, was susceptible to both study drugs. Patients who were pregnant or breastfeeding, or who were hypersensitive to /J-lactam antibiotics were excluded as were those with hepatic failure or coma, those who were neutropenic and those with a history of central nervous system (CNS) disease, osteomyelitis, endocarditis or cystic fibrosis. Patients who had been given antibiotic treatment within three days before study entry were also excluded unless the pathogen was shown to be resistant to the antimicrobial agents used or had not been eradicated. Each patient could enter the study only once.
Definition of infection
Infection diagnosis was based on the criteria of the Centers for Disease Control (Garner et al., 1988) . A lower respiratory tract infection (LRTI) was considered as acquired either in the community or in the hospital and a urinary tract infection (UTI) as either complicated or uncomplicated. Other infections included those involving skin and soft tissue, intra-abdominal infections and sepsis accompanied by bacteraemia. For patients with multiple sites of infection, the investigator designated the most serious one as the primary site of infection and additional sites were ranked in order of importance.
Treatment
Treatment was started empirically after appropriate samples from the infected site had been taken for culture. Cultures for bacteriological assessment and samples for baseline laboratory variables were obtained immediately before treatment and the medical history and signs and symptoms of infection were recorded. The overall condition of the patient at entry was assessed using the APACHE II scoring system (Knaus et al., 1985) . Patients were randomised to receive 1 g of either meropenem or imipenem/cilastatin intravenously every 8 h. Meropenem was administered either as a short infusion over 20-30 min or as an iv injection over 5 min and imipenem/cilastatin was administered by infusion over 40-60 min in order to minimise the incidence of nausea and vomiting (Norrby et al., 1987) . Treatment for a minimum of 48 h was required for assessing efficacy and could be continued for a maximum of 28 days. The dose and/or the frequency of meropenem was adjusted according to creatinine clearance when a patient had renal impairment and the dose and/or frequency of imipenem/cilastatin was adjusted according to renal function as recommended by the manufacturer. No other antibiotic was permitted. Other concomitant medications and any interventions were noted in the case record form of each patient.
Clinical assessment
Clinical signs and symptoms associated with infection, including peak body temperature, were recorded daily during treatment. At the end of therapy, the clinical status was evaluated to assess the overall patient response. The clinical response was based on the resolution of signs and symptoms and was considered 'satisfactory' when either the infection had been cured or there had been improvement in the patient's condition. The response was considered 'unsatisfactory' when either the patient's condition was unchanged or worse or when infection relapsed after treatment during the 2-4 weeks follow-up or 4-6 weeks, in the case of UTI. Treatment was considered unevaluable when the patient failed to satisfy all the inclusion and exclusion criteria or had died within 48 h of starting treatment as a result of the underlying disease. In addition, an incorrect diagnosis at the start of treatment, the administration of other antibiotics and failure to adhere to the protocol also rendered treatment unevaluable. Haematological and biochemical tests were performed immediately before treatment, after 2-3 days of treatment, at least once weekly thereafter during treatment and immediately after the end of treatment. If a clinically significant laboratory abnormality was detected, further samples were taken at regular intervals until the value returned to normal or to that found pretreatment.
Bacteriological assessment
Appropriate specimens were obtained for culture from infection sites immediately before starting treatment, during treatment when indicated, immediately after treatment had been discontinued and at 2-4 weeks follow-up if possible. For UTI, urine was obtained before treatment and after 48-72 h treatment, 5-9 days post treatment and at 4-6 weeks after the end of treatment to assess for relapse or reinfection. Mid-stream and catheter specimens of urine were cultured semiquantitatively and treatment was only considered successful if cultures yielded < K^cfu/mL by 48-72 h treatment and yielded no growth when obtained 5-9 days post treatment. Further specimens were obtained for culture from any new infection occurring at the original sites of infection (i.e. superinfection) or a different site during treatment only when clinically indicated. All organisms that were considered pathogens were identified to genus and species according to standard criteria and their antibiotic susceptibility testing was determined by disc diffusion according to the criteria recommended by the American National Committee for Clinical Laboratory Standards (NCCLS) (NCCLS, 1990) . MICs were also determined in Mueller-Hinton medium for aerobes and Wilkins Chalgren medium for anaerobes (Oxoid) using the appropriate standard (NCCLS, 1990) except that an inoculum of 10*cfu/mL was employed for anaerobes. All tests were incubated at 35-37°C for 18-24 h together with appropriate control strains. Resistance to meropenem was defined as an MIC > 8 mg/L or a zone diameter ^lOrnm and resistance to imipenem by an MIC > 8 mg/L or a zone diameter < 13 mm (NCCLS 1990 ).
The bacteriological response was evaluated at the end of therapy and at follow-up for each patient and was considered satisfactory when the original pathogen or pathogens had been eradicated or were presumed to have been eradicated when further specimens were not considered justified because there had been clinical cure or improvement. Any new infection due to a pathogen different from the original one that developed during or at the end of treatment was only considered a superinfection if it required antibiotic therapy or surgical treatment, otherwise it was considered to represent colonisation.
Safety assessment
The treatment of all patients was evaluated for safety by noting details of any adverse event in the case record form whether or not it was considered to be related to study drug treatment.
Statistics
Treatments were compared using a ^2-test based on a normal approximation to the binomial. The 95% confidence interval for the difference in proportions was also calculated. Based on a 70% clinical response for imipenem/cilastatin and a bacteriologically evaluable rate of 65%, it was estimated that 100 patients in each treatment group would be sufficient to detect a 20% higher satisfactory response rate for meropenem with a power of 76% and a type I error of 5%.
Results
Of the 204 patients that were recruited into the study, 106 received meropenem. The treatment of 90 patients with meropenem was considered evaluable for clinical efficacy as was the treatment of 87 with imipenem/cilastatin. The treatment of six patients was not evaluable for clinical efficacy because they died of their underlying disease within 48 h of starting treatment, the diagnosis was incorrect in a further three cases and other antibiotics were given in another three cases. In addition, a further 11 cases were unevaluable as a result of a protocol violation and two patients in each treatment group were excluded because they had infections due to resistant pathogens. The treatment of 61 and 54 patients with meropenem and imipenem/cilastatin respectively was evaluable for bacteriological efficacy.
Patient demography
The demography and baseline characteristics for clinically evaluable patients are shown in Table I . The two treatment groups were well balanced with respect to sex, age and weight. Approximately two thirds of patients in each treatment group were in intensive care, half the patients (53%) had failed to respond to antibiotic therapy before entering the study and a similar proportion was receiving assisted ventilation (59%). The types of infection treated in each treatment group were also similar but 15 (17%) patients in the meropenem treatment group had more than one site of infection compared with nine (10%) in the imipenem/cilastatin treatment group. More patients in the meropenem treatment group were severely ill than were those in the imipenem/cilastatin treatment group as 20 (22%) of the former had APACHE II scores >20 compared with 12 (14%) in the latter group.
Sites of infection
Most patients in both treatment groups had either hospital-acquired LRTI (80 patients; 45%) or intra-abdominal infection (75 patients; 42%) ( Table I) . Twenty-five (69%) of those given meropenem for a hospital acquired LRTI were diagnosed as having pneumonia as were 35 (79%) of those given imipenem/cilastatin. Seven of the patients treated with meropenem for a hospital acquired LRTI also had an additional site of infection (five intra-abdominal infection, one bacteraemia due to Klebsiella pneumoniae arising from pneumonia and one skin and soft tissue infection) as did six in the imipenem/cilastatin treatment group, (two with complicated UTI, two with skin and soft tissue infection and two with intra-abdominal infection of which one was accompanied by bacteraemia due to K. pneumoniae and Pseudomonas aeruginosa.
Of the 75 patients who had intra-abdominal infections, 57 (76%) presented with diffuse or generalised peritonitis and 24% with abscesses. The origin of infection was similar for the meropenem and imipenem/cilastatin group respectively: colon/rectum nine and 12 cases, stomach or duodenum nine and eight cases, peritonitis seven and five cases, appendix six cases each, biliary, liver or pancreas five and three cases and small bowel two and three cases. In addition to the seven cases with both abdominal infection and a hospital acquired LRTI already mentioned, abdominal infection was accompanied by complicated UTI in one case treated with meropenem and bacteraemia in two cases due to Escherichia coli. In the imipenem/cilastatin treatment group there was one case accompanied by a skin and soft tissue infection, and one case accompanied by bacteraemia due to E. coli.
Fifteen patients with community acquired LRTI were diagnosed as having bronchopneumonia or pneumonia. Six patients in the meropenem treatment group had both chronic obstructive pulmonary disease and pneumonia.
The ten patients with skin and soft tissue infections included three with abscesses, two each with decubitis ulcers and wound infections and one each with a subcutaneous abscess, facial submandibular cellulitis and eschars. The nine complicated UTI cases comprised three cases each with pyelonephritis and complicated cystitis, two cases of bacteriuria due to Acinetobacter baumanii and E. coli respectively and one case of renal infection. The single case of meningitis treated with meropenem was due to Staphylococcus epidermidis and the case of mediastinitis treated with imipenem/cilastatin resulted from a previous oesophagectomy.
In the meropenem treatment group there were also two cases of bacteraemia due to Serralia marcescens and E. coli respectively that were associated with skin and soft tissue infections. One case of community acquired LRTI was accompanied by bacteraemia due to Streptococcus pneumoniae and there were two cases of bacteraemia accompanied by sepsis due to a group C Streptococcus sp. and E. coli respectively.
In the imipenem/cilastatin treatment group there was a single case of bacteraemia due to Acinetobacter haemolyticus which accompanied a skin and soft tissue infection.
Duration of treatment
The mean duration of meropenem treatment was 10.7 days (S.D. + 6.4; range 3-36) compared with 11.5 days (S.D. ± 6.9; range 3-36) of treatment with imipenem/cilastatin. The mean number of doses of meropenem and imipenem/cilastatin given was 27.5 and 31.3, respectively.
Overall clinical outcome
Treatment with meropenem was satisfactory for all infections in 68 (76%) of the 90 patients and imipenem/cilastatin for 67 (77%) of the 87 patients (Table II) . Of the 22 patients for whom meropenem proved unsatisfactory, 13 had presented with a single site of infection. The remaining nine cases had two evaluable sites of infection, both of which failed to respond to treatment in three cases and in three cases each there was a lack of improvement of the primary or secondary infection respectively.
Of the 20 patients who failed to respond satisfactorily to imipenem/cilastatin treatment, 15 had presented with a single infection which failed to respond. Of the five patients who had presented with more than one site of infection, treatment of the primary infection was unsatisfactory in one case, the secondary infection did not respond in two cases and neither infection improved in two cases.
Relationship of A PA CHE II score to outcome
The relationship of clinical failure to APACHE II score was similar for the meropenem and imipenem/cilastatin treatment groups respectively. In the meropenem treatment group, two (7%) of the 27 with APACHE II scores <10, 11 (27%) of the 41 with APACHE II scores between 11 and 20 and eight (40%) of the 20 with higher scores responded unsatisfactorily. The corresponding results for the imipenem/cilastatin treatment were, respectively, three (11%) of 27, nine (20%) of 45 and five (42%) of 12 patients.
Relapses
Two cases of hospital acquired LRTI and one each of complicated UTI and intra-abdominal infection satisfactorily treated with meropenem experienced a relapse during the follow-up period as did five cases of hospital acquired LRTI and three cases of intra-abdominal infection satisfactorily treated with imipenem/cilastatin.
Satisfactory outcome rates for hospital acquired LRTI
For hospital acquired LRTI, satisfactory clinical response rates of 75% were obtained for both treatment groups (difference 0%; 95% Cl: -19.1%, 19.1%) and satisfactory 
Satisfactory outcome rates for intra-abdominal infection
Satisfactory clinical response rates of 81.6% and 81.1% were obtained respectively with meropenem and imipenem/cilastatin for the treatment of intra-abdominal infection (difference 0.5%; 95% Cl: -17.1, 18.1%). Of the seven patients in both groups for which treatment was unsatisfactory, six patients treated with meropenem and five treated with imipenem/cilastatin patients had entered the study with infections arising from previous surgery. A similar satisfactory bacteriological response rate of 68.0% and 70.4% was observed after treatment with meropenem and imipenem/cilastatin respectively (difference 2.4%; 95% Cl: -27.5, 22.8%). Of the bacteriologically evaluable patients with intra-abdominal infection 35 of 52 (67%) patients had polymicrobial infections. Fifteen had been treated with meropenem and 20 with imipenem/cilastatin with satisfactory clinical response rates of 80% and 70% being found respectively and bacteriological response rates of 67% and 68% respectively.
Satisfactory outcome rates for other infections
The clinical and bacteriological response rates for the other infections were similar for both treatments with 22 of 31 (71%) responding clinically to meropenem and 11 of 16 (69%) to imipenem/cilastatin with corresponding bacteriological response rates of 15 of 20 (75%) and 7 of 8 (88%). Further analysis was not undertaken because of the small numbers of patients involved.
Bacteriological eradication rates
Of the 219 organisms isolated, Gram-negative aerobic bacteria accounted for 131 (60%), Gram-positive bacteria for 61 (28%) and anaerobes for the remainder (Table III) . E. coli, K. pneumoniae and Haemophilus influenzae were consistently eradicated by both drugs, unlike other species particularly P. aeruginosa.
Five of the nine isolates of P. aeruginosa that were either presumed or proven to have persisted in the meropenem treatment group were associated with clinical failure of treatment (two intra-abdominal infection, two hospital acquired LRTI and one skin and soft tissue infection). A satisfactory clinical response was obtained for four hospital acquired LRTIs, one of which later relapsed. Similarly, four of the ten P. aeruginosa persisted despite a satisfactory clinical response to imipenem/cilastatin in three cases with hospital acquired LRTI, one of which later relapsed and a single case of bacteraemia which was associated with clinical failure.
Enterococcus faecalis was isolated seven times in the meropenem treatment group and eleven times in those treated with imipenem/cilastatin, and was presumed or proven to have persisted in two cases in each treatment group involving patients with polymicrobial intra-abdominal sepsis who did not show any clinical improvement with either study treatment. In contrast, very high eradication rates were achieved against the anaerobes with both treatment regimens.
The organism involved in seven of the eight episodes of bacteraemia treated with meropenem was eradicated and in two of the three cases treated with imipenem/ cilastatin (Table III) .
Superinfections
Among the patients evaluable for bacteriological outcome, superinfections due to susceptible organisms were diagnosed in five patients in each treatment group. In the meropenem group one patient had a superinfection due to S. epidermidis and two different enterococci, another had an infection due to S. epidermidis and Proteus mirabilis. The other three cases involved respectively, E. coli, Enterobacter cloacae and P. mirabilis. In the imipenem/cilastatin treatment group one patient had a superinfection due to Alcaligenes xylosoxidans and E. faecalis and another had superinfection due to Pseudomonas sp. and S. epidermidis. Superinfections due to Staphylococcus aureus, E. coli and P. mirabilis were detected in one case each.
Superinfection due to resistant Stenotrophomonas maltophilia (at two different sites) affected one patient from each treatment group. Another patient treated with meropenem developed a superinfection due to methicillin resistant S. epidermidis. One patient developed a superinfection at five different sites during treatment with imipenem/cilastatin, bacteraemia due to methicillin resistant S. epidermidis, wound infection due to both methicillin resistant S. aureus and P. aeruginosa, and P. aeruginosa was also isolated from urine, gastric fluid and the oropharynx. One further patient developed a superinfection due to P. aeruginosa during treatment with imipenem/ cilastatin. These superinfections all developed after at least three days of treatment.
An unidentified yeast was responsible for superinfection in two cases in the meropenem treatment group and for one in the imipenem/cilastatin treatment group, and Candida albicans was responsible for a further two cases in the latter group.
Safety and tolerance
Thirty-nine (37%) of the 106 patients treated with meropenem experienced one or more adverse events compared with 34 (35%) of the 98 who received imipenem/cilastatin, although in only ten (9%) and 12 (12%) of cases respectively were the adverse events judged to have been related to the study drug. These included diarrhoea and rash in two cases each treated with meropenem, two cases of inflammation at the injection site during meropenem treatment and one during imipenem/cilastatin treatment, elevated alkaline phosphatase or ALT in two cases each treated with meropenem and in eight and one case treated with imipenem/cilastatin. There were two cases of leucopenia in the imipenem/cilastatin group which led to withdrawal from the study in one case. Fourteen patients died during treatment with meropenem as did 12 who had been given imipenem/cilastatin. A further ten patients died during the 28 day follow-up period after treatment with meropenem and a further five patients after therapy with imipenem/cilastatin. Infection may have contributed to 15 deaths in the meropenem group and to ten deaths in the imipenem/cilastatin group, although none of the deaths was considered to have been related to study treatment but reflected the poor condition of these patients and the risk of death corresponded with a higher APACHE II score.
Discussion
This present study was undertaken to compare imipenem/cilastatin with the new carbapenem, meropenem, for the treatment of serious bacterial infections. Both agents possess a sufficiently broad spectrum of antimicrobial activity to permit their use for empirical monotherapy which is important in intensive care units where antimicrobial treatment is often started before the results of culture are known. Monotherapy with these agents also has several other advantages over combination therapy by helping to limit the use of potentially nephrotoxic drugs, obviating the need to monitor serum concentrations, and by allowing a simplified treatment regimen to be used that reduces the risk of adverse reactions occurring.
In our study, Gram-negative bacilli (60%) clearly predominated as causes of infection which is in accordance with recent hospital data (Vincent et al., 1995) and might have been the result of patient selection, previous antibiotic treatment and the high frequency of LRTIs.
The study demonstrated that empirical monotherapy with both meropenem and imipenem/cilastatin was effective in treating approximately 75% of patients all of whom were seriously ill patients with either single or multiple infections. These results are impressive considering the fact that more than 53% of the patients had been treated unsuccessfully beforehand or were dependent upon ventilators. However, the success of treatment depended upon the physiological status of the patient as failure was directly related to the APACHE II score.
The carbapenems are highly potent antimicrobial agents but there is concern that resistance might emerge with the attendant risk of cross infection. One new isolate of P. aeruginosa was encountered during the study which was resistant to meropenem and four new isolates resistant to imipenem. There was also some selection of organisms predominantly resistant to carbapenems including S. maltophilia, methicillin resistant 5. aureus and methicillin resistant S. epidermidis. Additional strategies might therefore be necessary to combat pathogens such as P. aeruginosa in which resistance might develop during treatment. However, since carbapenem resistance did not emerge until after at least 3 days of treatment, initial monotherapy with these drugs would appear feasible until the results of culture and susceptibility tests are known.
In treating serious infections due to P. aeruginosa in the ICU it is particularly important to administer the optimal dose of any /Mactam antibiotic used for therapy. This ensures that plasma concentrations exceed the MIC for the organism for an adequate length of time and lowers the risk of emergent resistance which can occur when 500 mg imipenem/cilastatin is given qds (Norrby et al., 1993) .
Meropenem has been well tolerated at doses up to 6 g/day for the treatment of meningitis (Schmutzhard et al., 1995) and therefore, at least on theoretical grounds, it should be possible to escalate the meropenem dose to 2 g 8-hourly in patients infected with organisms considered difficult to treat such as P. aeruginosa in order to increase the time for which the plasma concentration exceeds the MIC for the pathogen. Dose escalation beyond 4 g/day is not practical with imipenem/cilastatin because higher doses are associated with an increased incidence of nausea and vomiting (Wang et al., 1985; Pedersen et al., 1987) , and seizures (Calandra et al., 1988) . Continuous infusion of the carbapenems might be another possible alternative to giving intermittent doses but there are no clinical data available. Further data on meropenem's stability for continuous infusion are needed although one study of pharmacokinetics has already been reported (Mouton & Michel, 1991) . It is already known that imipenem is unstable in solution and should therefore be given intermittently (Craig, 1995) .
Supplementing therapy with a specific antipseudomonal drug, such as an aminoglycoside, could be an alternative to increasing the dose of the carbapenem in order to prevent the emergence of resistant strains and, in so doing, to reduce the incidence of failures and superinfections. However, there are no clinical data on combinations of meropenem with other antipseudomonal drugs although some synergy with aminoglycosides against multiply resistant isolates of P. aeruginosa has been noted in vitro suggesting at least a theoretical benefit for adding an aminoglycoside when required (Baltch, Smith & Ritz, 1995; Giamarellos-Bourboulis et al., 1995) . Never the less, the emergence of resistant strains of Pseudomonas spp. was not prevented in a study reported by Cometta et al. (1994) where imipenem/cilastatin was administered with netilmicin for the treatment of severe infections in non-neutropenic patients. However, imipenem/cilastatin was given at the lower dose of 500 mg qds which may have been suboptimal and it could also be argued that netilmicin is, perhaps, not the most appropriate of the aminoglycosides to use against P. aeruginosa. Clearly, treatment of infections caused by this organism can pose difficulties even with potent antibacterial agents such as meropenem. It is therefore important to ensure the drug is given in optimal doses i.e. 1 g tds and to determine the susceptibility of the pathogen so that meropenem can be complemented by another appropriate agent if required.
In the present study meropenem was as well tolerated as imipenem/cilastatin although patients with a history of CNS disease were specifically excluded to reduce the chance of CNS side effects occurring during treatment with imipenem/cilastatin. Although approximately one third of the patients experienced adverse events, none of those deemed serious were considered to have been related to the study drug, and only one patient treated with imipenem/cilastatin was withdrawn because of an adverse event. The overall mortality seen in this study reflected the poor clinical condition of the patients and corresponded to the APACHE II score (Knaus et al., 1985) .
In summary, both carbapenems are effective for the empirical monotherapy of patients with serious bacterial infections in the ICU, at least until the results of culture and susceptibility tests become available to allow treatment to be adjusted if necessary.
